Alemao E, et al. - Individuals with established RA were recognized through administrative claims data related to laboratory results (2005–2016) in order to assess the correlation of antibody titers with mortality and its modification by disease-modifying antirheumatic drugs (DMARDs). Overall, 53,849 and 79,926 individuals, respectively, had evaluable anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) status. For both autoantibodies, in seropositive vs seronegative individuals, mortality rates were significantly greater. In individuals with higher vs lower autoantibody titers, mortality rates were greatest. In cDMARD-exposed individuals, in seropositive cohorts had greater HRs, compared with seronegative cohorts and in bDMARD-exposed patients, no variation in mortality by serostatus was found. Hence, among patients with RA and continued in cases treated with cDMARDs, raised ACPA/RF titers were irrespectively related to heightened mortality, however, not with bDMARDs.